Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

Abstract The Drug-Gene Interaction Database (DGIdb, www. dgidb. org) is a web resource
that provides information on drug-gene interactions and druggable genes from publications …

PURPOSE Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ)
chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) …

Purpose: Intrapatient heterogeneity of programmed death ligand 1 (PD-L1) expression and
tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) could …

Importance There are few studies assessing the association of tumor mutational burden
(TMB) and clinical outcomes in a large cohort of patients with diverse advanced cancers …

PURPOSE Promising single-agent activity from sotorasib and adagrasib in KRAS G12C-
mutant tumors has provided clinical evidence of effective KRAS signaling inhibition …

Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer
biology and develop novel precision medicine therapeutics. However, utilizing TOs for …

We investigated the challenges of conducting IMPACT2, an ongoing randomized study that
evaluates molecular testing and targeted therapy (ClinicalTrials. gov: NCT02152254) …

Background Colorectal cancer (CRC) consensus molecular subtypes (CMS) have different
immunological, stromal cell, and clinicopathological characteristics. Single-cell …